Evidence map›Paper›PMID 28785154›Full record

SynthesisWorld journal of gastroenterology2017

Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis.

Camila Ribeiro de Avelar, Emile Miranda Pereira, Priscila Ribas de Farias Costa, Rosângela Passos de Jesus, Lucivalda Pereira Magalhães de Oliveira

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in World journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Camila Ribeiro de AvelarCamila Ribeiro de Avelar, Emile Miranda Pereira, Post-graduation Program, Federal University of Bahia, Salvador, Bahia 40.110-150, Brazil.
Emile Miranda PereiraCamila Ribeiro de Avelar, Emile Miranda Pereira, Post-graduation Program, Federal University of Bahia, Salvador, Bahia 40.110-150, Brazil.
Priscila Ribas de Farias CostaCamila Ribeiro de Avelar, Emile Miranda Pereira, Post-graduation Program, Federal University of Bahia, Salvador, Bahia 40.110-150, Brazil.
Rosângela Passos de JesusCamila Ribeiro de Avelar, Emile Miranda Pereira, Post-graduation Program, Federal University of Bahia, Salvador, Bahia 40.110-150, Brazil.
Lucivalda Pereira Magalhães de OliveiraCamila Ribeiro de Avelar, Emile Miranda Pereira, Post-graduation Program, Federal University of Bahia, Salvador, Bahia 40.110-150, Brazil.
Universidade Federal da Bahia · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo evaluate the effect of silymarin on the serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma glutamyl transpeptidase (γGT) in patients with liver diseases.

methodsA systematic review with meta-analysis of ramdomized and controlled clinical trials was performed, evaluating the effects of sylimarin in patients with hepatic diseases, published by January 31, 2016. Clinical trials were sought on the basis of The Cochrane Central Register of Controlled Trials in the Cochrane Library, PubMed/Medline, Scopus, Web of Science, Lilacs and Clinical Trials. The trials with adult and elderly patients of both sexes, with Liver Diseases who took oral silymarin supplementation, as extract or isolated, as well as Silymarin combined with other nutrients, were included. The trials should provide information about the intervention, such as dosages and detailing of the product used, besides the mean and standard deviation of serum levels of ALT, AST and γGT of the baseline and at the end of the intervention.

resultsAn amount of 10904 publications were identified. From those, only 17 were included in the systematic review and 6 in the meta-analysis, according to the used selection criteria. In this meta-analysis, the results indicated a reduction of 0.26 IU/mL (95%CI: -0.46-0.07,

conclusionSilymarin minimally reduced, but without clinical relevance, the serum levels of ALT and AST. It is necessary to carry out studies with more appropriate methodological designs.

Indexed as

Alanine TransaminaseAspartate Aminotransferasesgamma-GlutamyltransferaseHumansLiverLiver DiseasesProtective AgentsRandomized Controlled Trials as TopicSilymarinAlanine TransaminaseAspartate Aminotransferasesgamma-GlutamyltransferaseProtective AgentsSilymarinLiver diseasesMeta-analysisMilk thistleSilymarinSystematic review

Identifiers

PMID28785154
PMCPMC5526770
OpenAlexW2738189019

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.